SavedAdd your journal

Journals / Güncel Retina Dergisi / 2017 / Cilt: 1 - Sayı: 3

Aflibercept Treatment and Treatment Algorithms in Wet-Form (Neovascular) Age-Related Macular Degeneration

Yaş Tip (Neovasküler) Yaşa Bağlı Maküla Dejenerasyonunda Aflibercept Tedavisi ve Tedavi Algoritmaları

MEHMET ÇITIRIK
Çağrı İLHAN
MEHMET YASİN TEKE
Pages
198–205
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review mentions about the aflibercept treatment and treatment algorithms in wet-form (neovascular) age-related macular degeneration

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Age-related macular degeneration (AMD) commonly develops after the age of 50.
📊
Key Findings & Data:AMD is a progressive degenerative disorder of the macula in which central vision becomes impaired and leading cause of blindness.
💡
Conclusion & Impact:This review mentions about the aflibercept treatment and treatment algorithms in wet-form (neovascular) age-related macular degeneration
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Age-related macular degeneration (AMD) commonly develops after the age of 50. AMD is a progressive degenerative disorder of the macula in which central vision becomes impaired and leading cause of blindness. Severe vision loss occurs in the late stages of the disease. Untreated wet-form (neovascular) AMD leads to a rapid loss of vision in the affected eye. Many studies have shown vascular endothelial growth factor (VEGF) as a key mediator in wet-form (neovascular) AMD. This review mentions about the aflibercept treatment and treatment algorithms in wet-form (neovascular) age-related macular degeneration

Özet

Yaşa bağlı maküla dejenerasyonu (YBMD), sıklıkla 50 yaşından sonra gelişir. YBMD, makülanın progresif dejeneratif bir hastalığı olup merkezi görme bozukluğu ve körlüğün önde gelen nedenlerindendir. Ağır görme kaybı, hastalığın geç evrelerinde görülür. Tedavi edilmeyen yaş-tip (neovasküler) YBMD, etkilenen gözde hızla görme kaybına neden olur. Birçok çalışma, yaş-tip (neovasküler) YBMD'de vasküler endotelyal büyüme faktörünü (VEGF) önemli bir medyatör olarak göstermiştir. Bu derlemede yaş tip (neovasküler) yaşa bağlı maküla dejenerasyonunda aflibercept tedavisi ve tedavi algoritmaları ele alınmıştır

🔖

Cite This Article

ÇITIRIK, M., İLHAN, Ç., TEKE, M. Y. (2017). Aflibercept Treatment and Treatment Algorithms in Wet-Form (Neovascular) Age-Related Macular Degeneration. Güncel Retina Dergisi, Cilt: 1 - Sayı: 3, 198–205. https://ajindex.com/articles/198376

References (15)

  1. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2): e106-16
  2. Erol N. Vasküler Endotelyal Büyüme Faktörü ve Anti-VEGF Ajanlar. RetVit 2007;15 (Özel Sayı): 35-40
  3. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005; 9(4): 777-94
  4. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol. 2006; 142(4): 660-8
  5. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006; 90(12): 1542-7
  6. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8): 579-91
  7. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991; 5(12): 1806-14
  8. Yazır Y. Vasküler Endotel Büyüme Faktörü (Vegf):Reseptörleri ve Fonksiyonları. C.Ü. Tıp Fakültesi Dergisi 2007; 29 (3): 128-136
  9. Xu D, Kaiser PK. Intravitreal aflibercept for neovascular age-related macular degeneration. Immunotherapy. 2013; 5(2): 121-30
  10. Frampton JE. Aflibercept for intravitreal injection: in neovascular age-related macular degeneration. Drugs Aging. 2012; 29(10): 839-46
  11. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012; 119(12): 2537-48
  12. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5):855–859
  13. Stewart MW. What are the half-lives of ranibizumab and aflibercept (VEGF trap-eye) in human eyes? Calculations with a mathematical model. Eye Rep. 2011;1(e5): 12-4
  14. Thai HT, Veyrat-Follet C, Vivier N, Dubruc C, Sanderink G, Mentre´ F, et al. A mechanism-based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. Br J Clin Pharmacol. 2011; 72(3): 402–14
  15. Nguyen QD, Shah SM, Hafiz G, et al; CLEAR-AMD 1 Study Group. A phase I trial of an IV-administered vascular endothelial grow